Brokerages expect Akebia Therapeutics Inc (NASDAQ:AKBA) to report ($0.35) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Akebia Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.41). Akebia Therapeutics posted earnings per share of ($0.60) in the same quarter last year, which indicates a positive year-over-year growth rate of 41.7%. The company is expected to issue its next earnings report on Wednesday, August 14th.
On average, analysts expect that Akebia Therapeutics will report full year earnings of ($1.75) per share for the current fiscal year, with EPS estimates ranging from ($2.28) to ($1.41). For the next fiscal year, analysts forecast that the business will post earnings of ($0.63) per share, with EPS estimates ranging from ($1.66) to $0.38. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Akebia Therapeutics.
Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.02). The firm had revenue of $72.67 million for the quarter, compared to analysts’ expectations of $83.69 million. Akebia Therapeutics had a negative net margin of 82.14% and a negative return on equity of 45.06%.
Large investors have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC grew its holdings in Akebia Therapeutics by 5.9% during the fourth quarter. MetLife Investment Advisors LLC now owns 40,608 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 2,250 shares during the last quarter. Strs Ohio grew its holdings in Akebia Therapeutics by 5.4% during the first quarter. Strs Ohio now owns 45,100 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 2,300 shares during the last quarter. Virginia Retirement Systems ET AL grew its holdings in Akebia Therapeutics by 18.2% during the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 2,500 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Akebia Therapeutics by 20.5% during the first quarter. DekaBank Deutsche Girozentrale now owns 20,600 shares of the biopharmaceutical company’s stock valued at $170,000 after purchasing an additional 3,500 shares during the last quarter. Finally, Boston Partners grew its holdings in Akebia Therapeutics by 1.3% during the first quarter. Boston Partners now owns 283,044 shares of the biopharmaceutical company’s stock valued at $2,318,000 after purchasing an additional 3,666 shares during the last quarter. Hedge funds and other institutional investors own 70.50% of the company’s stock.
Shares of AKBA traded up $0.21 during trading hours on Friday, reaching $4.84. The company’s stock had a trading volume of 7,308,094 shares, compared to its average volume of 1,156,008. The company has a market cap of $545.70 million, a price-to-earnings ratio of -1.98 and a beta of 1.51. Akebia Therapeutics has a 1-year low of $4.09 and a 1-year high of $10.73. The company has a current ratio of 1.71, a quick ratio of 1.15 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $4.85.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.